• Playlist
  • Download
  • Embed
    Embed <iframe src="" width="100%" height="290" frameborder="0" scrolling="no">
  • Transcript

Last year, stocks in a small Manhattan-based biotech company, ImClone, soared on the promise of its new cancer-fighting drug, Erbitux. At the end of 2001, the Food and Drug Administration refused to accept the company's application for approval of the drug. Imclone is now facing allegations that it deliberately misled investors about the drug's status. NPR's Snigdha Prakash reports the story has now taken another turn.



Please keep your community civil. All comments must follow the Community rules and terms of use, and will be moderated prior to posting. NPR reserves the right to use the comments we receive, in whole or in part, and to use the commenter's name and location, in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.